Literature DB >> 7650125

Intravenous albumin does not prevent the development of severe ovarian hyperstimulation syndrome in an in-vitro fertilization programme.

E Ng1, A Leader, P Claman, M Domingo, J E Spence.   

Abstract

A cohort study was undertaken to compare the effect at the time of oocyte retrieval of the i.v. administration of either 1000 ml of lactated Ringer's solution or 1000 ml of a 5% solution of human albumin on in-vitro fertilization patients at risk for severe ovarian hyperstimulation syndrome (OHSS). A total of 207 patients with an oestradiol concentration > 10,000 pmol/l and/or > 15 follicles (> 10 mm diameter) on the day of human chorionic gonadotrophin (HCG) injection were reviewed. Of these, 158 women received 500 ml of lactated Ringer's solution both before and after egg retrieval, and 49 women received two infusions of 500 ml of 5% human albumin in normal saline at the time of egg retrieval. Severe OHSS developed in two patients who received human albumin and in 10 women who did not receive the albumin. This difference was not statistically significant. There were no differences between the two groups in terms of age, number of follicles punctured at transvaginal oocyte retrieval or oestradiol concentration at the time of HCG injection. The administration of a 5% human albumin solution does not prevent the development of severe OHSS in at risk patients. It does appear to blunt the severity of the condition.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7650125     DOI: 10.1093/oxfordjournals.humrep.a136043

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  4 in total

Review 1.  Safety of drugs used in assisted reproduction techniques.

Authors:  Talha Al-Shawaf; Ariel Zosmer; Martha Dirnfeld; Gedis Grudzinskas
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 2.  VEGF antagonist for the prevention of ovarian hyperstimulation syndrome: Current status.

Authors:  Nikita Naredi; Pankaj Talwar; K Sandeep
Journal:  Med J Armed Forces India       Date:  2012-09-11

3.  Cabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoing in vitro fertilization/intracytoplasmic sperm injection treatment cycles: A randomized controlled study.

Authors:  Niyazi Kılıç; Özhan Özdemir; Hakan Cevdet Başar; Fadime Demircan; Fırat Ekmez; Oğuz Yücel
Journal:  Avicenna J Med       Date:  2015 Oct-Dec

Review 4.  Volume expanders for the prevention of ovarian hyperstimulation syndrome.

Authors:  Mohamed A Youssef; Selma Mourad
Journal:  Cochrane Database Syst Rev       Date:  2016-08-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.